Sandoz receives Health Canada approval for Jubbonti ®, first and only denosumab biosimilar for treatment of osteoporosis

Biosimilar Jubbonti® approved for all indications of Prolia* reference medicine. • Sandoz continues to expand access for patients in Canada, offering denosumab biosimilar to treat osteoporosis and increase bone mass. • Results confirm that Jubbonti® provides same risks and benefits in terms of…#prolia #sandoz #boucherville #quebec #sandozcanada #healthcanada #jubbonti #canada1 #jeanpierreraynauld #frcpc
Source: Reuters: Health - Category: Consumer Health News Source Type: news